Next Article in Journal
Apo-9′-Fucoxanthinone, Isolated from Sargassum muticum, Inhibits CpG-Induced Inflammatory Response by Attenuating the Mitogen-Activated Protein Kinase Pathway
Next Article in Special Issue
Smenamides A and B, Chlorinated Peptide/Polyketide Hybrids Containing a Dolapyrrolidinone Unit from the Caribbean Sponge Smenospongia aurea. Evaluation of Their Role as Leads in Antitumor Drug Research
Previous Article in Journal
Epigonal Conditioned Media from Bonnethead Shark, Sphyrna tiburo, Induces Apoptosis in a T-Cell Leukemia Cell Line, Jurkat E6-1
Previous Article in Special Issue
Diversity of Secondary Metabolites from Marine Bacillus Species: Chemistry and Biological Activity
Mar. Drugs 2013, 11(9), 3258-3271; doi:10.3390/md11093258
Article

Cyclodextrin Formulation of the Marine Natural Product Pseudopterosin A Uncovers Optimal Pharmacodynamics in Proliferation Studies of Human Umbilical Vein Endothelial Cells

1
, 2
, 1,2
 and 3,*
Received: 5 July 2013; in revised form: 13 August 2013 / Accepted: 14 August 2013 / Published: 26 August 2013
(This article belongs to the Special Issue Marine Secondary Metabolites)
View Full-Text   |   Download PDF [842 KB, uploaded 26 August 2013]   |   Browse Figures
Abstract: Pseudopterosin A (PsA) treatment of growth factor depleted human umbilical vein endothelial cell (HUVEC) cultures formulated in hydroxypropyl-β-cyclodextrin (HPβCD) for 42 h unexpectedly produced a 25% increase in cell proliferation (EC50 = 1.34 × 10−8 M). Analysis of dose response curves revealed pseudo-first order saturation kinetics, and the uncoupling of cytotoxicity from cell proliferation, thereby resulting in a widening of the therapeutic index. The formulation of PsA into HPβCD produced a 200-fold increase in potency over a DMSO formulation; we propose this could result from a constrained presentation of PsA to the receptor, which would limit non-specific binding. These results support the hypothesis that the non-specific receptor binding of PsA when formulated in DMSO has ostensibly masked prior estimates of specific activity, potency, and mechanism. Collectively, these results suggest that the formulation of PsA and compounds of similar chemical properties in HPβCD could result in significant pharmacological findings that may otherwise be obscured when using solvents such as DMSO.
Keywords: pseudopterosins; log P; human umbilical vein endothelial cells (HUVEC); proliferation; hydroxypropyl-beta-cyclodextrin (HPβCD) pseudopterosins; log P; human umbilical vein endothelial cells (HUVEC); proliferation; hydroxypropyl-beta-cyclodextrin (HPβCD)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Day, D.R.; Jabaiah, S.; Jacobs, R.S.; Little, R.D. Cyclodextrin Formulation of the Marine Natural Product Pseudopterosin A Uncovers Optimal Pharmacodynamics in Proliferation Studies of Human Umbilical Vein Endothelial Cells. Mar. Drugs 2013, 11, 3258-3271.

AMA Style

Day DR, Jabaiah S, Jacobs RS, Little RD. Cyclodextrin Formulation of the Marine Natural Product Pseudopterosin A Uncovers Optimal Pharmacodynamics in Proliferation Studies of Human Umbilical Vein Endothelial Cells. Marine Drugs. 2013; 11(9):3258-3271.

Chicago/Turabian Style

Day, Daniel R.; Jabaiah, Suraya; Jacobs, Robert S.; Little, R. D. 2013. "Cyclodextrin Formulation of the Marine Natural Product Pseudopterosin A Uncovers Optimal Pharmacodynamics in Proliferation Studies of Human Umbilical Vein Endothelial Cells." Mar. Drugs 11, no. 9: 3258-3271.


Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert